{"eventGroups":[{"description":"Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.\n\nindium In 111 anti-CD45 monoclonal antibody BC8: Given IV\n\nyttrium Y 90 anti-CD45 monoclonal antibody BC8: Given IV\n\nperipheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell transplant","id":"EG000","otherNumAffected":2,"otherNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"Treatment (Yttrium-90 Anti-CD45 Monoclonal Antibody BC8)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (Unspecified)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Hyperglycemia"}],"timeFrame":"AEs will be monitored and recorded in study-specific case report forms (CRFs) from the time of first exposure to the investigational product in this study (i.e., the start of the first dosimetry infusion) through day +30 post transplant or through discharge prior to that date from the SCCA system to care of the patient's primary physician"}